Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Bone Marrow Transplant ; 45(6): 1022-30, 2010 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-20118994

RESUMEN

Alloreactivity of natural killer (NK) cells contributes to the GVL reaction after allogeneic hematopoietic SCT (allo-HSCT). However, various procedure-related factors may affect NK cell maturation and their ability to recognize and kill leukemic cells. In this study, we prospectively evaluated expression of NK cell inhibitory receptors in 83 adults treated with myeloablative, killer cell Ig-like receptor (KIR)-ligand-matched allo-HSCT. NK cell maturation was evaluated by comparing the phenotypic patterns after allo-HSCT with the donor ones. The frequencies of KIR3DL1 were comparable to the donor ones on day +28, while they decreased significantly starting from day +100. The expression of KIR2DL2/3 was significantly lower in patients compared with donors up to day +100. The expression of KIR2DL1, despite continues growth, remained significantly decreased for 1 year after allo-HSCT. NKG2A was over-expressed up to day +180. Within 1 year after allo-HSCT, the NK cell phenotypic pattern tended to recapitulate the donor type. The process was disturbed by the use of steroids with significant differences observed on days +56 (P=0.01) and +100 (P=0.04). Up to day +100, reconstitution of NK cell receptor repertoire correlated with the absolute numbers of circulating CD3(+), CD3(+)CD4(+) and CD3(+)CD8(+) cells. Our observations should be taken into account when trying to predict potential benefit from NK cell alloreactivity.


Asunto(s)
Trasplante de Células Madre Hematopoyéticas/métodos , Inmunidad Innata/fisiología , Células Asesinas Naturales/citología , Receptores KIR/análisis , Regeneración , Adolescente , Adulto , Neoplasias Hematológicas/terapia , Trasplante de Células Madre Hematopoyéticas/mortalidad , Humanos , Persona de Mediana Edad , Agonistas Mieloablativos/uso terapéutico , Estudios Prospectivos , Receptores KIR2DL1/análisis , Receptores KIR2DL2/análisis , Receptores KIR2DL3/análisis , Receptores KIR3DL1/análisis , Receptores de Células Asesinas Naturales/análisis , Esteroides/administración & dosificación , Esteroides/farmacología , Factores de Tiempo , Donantes de Tejidos , Trasplante Homólogo , Adulto Joven
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA